#USA #New York #Class Action #Rosen Law Firm #Actinium Pharmaceuticals

Investors Urged to Take Action Against Actinium Pharmaceuticals

On March 29, 2025, the Rosen Law Firm, a leading law firm specializing in investor rights, made a significant announcement regarding Actinium Pharmaceuticals, Inc. (NYSE American: ATNM). They revealed the initiation of a class action lawsuit aimed at protecting investors who purchased Actinium's securities during a specified class period: from October 31, 2022, to August 2, 2024. This lawsuit arises from concerns over alleged securities fraud that misled investors about the viability of the company’s products and regulatory processes.

Understanding the Class Action Lawsuit

A class action lawsuit is a legal action filed on behalf of multiple individuals who have been similarly harmed. In this case, those who bought shares in Actinium within the defined timeframe may be entitled to compensation. The Rosen Law Firm is encouraging interested investors to come forward, especially those who wish to serve as lead plaintiffs. To do so, they must file their applications by May 26, 2025.

Why This Action Matters

The lawsuit centers around claims that Actinium, during the class period, made statements that were materially misleading regarding its drug development, particularly with their Iomab-B Biologics License Application (BLA). Defendants reportedly failed to disclose critical facts regarding the company’s data and its alignment with U.S. Food and Drug Administration (FDA) guidelines. This includes the likelihood that the trial data from their Sierra Trial would not satisfy FDA’s requirements for drug approval. Such omissions could significantly impact investors’ decisions, leading to financial harm when the facts were eventually revealed.

The Role of Rosen Law Firm

Rosen Law Firm stands out as a respected entity in supporting investors during challenging times. The firm has a history of securing substantial settlements in securities class actions, including notable cases against major companies. By prioritizing investor interests, they provide a platform for individuals to reclaim their losses without upfront costs, thanks to their contingency fee agreements.

How to Get Involved

Investors interested in joining the lawsuit against Actinium Pharmaceuticals can find further details by visiting their dedicated form page at Rosen Law Firm's Website. They can also contact Phillip Kim, Esq. toll-free at 866-767-3653 or by email at pk@rosenlegal.com for additional queries and guidance.

Upcoming Steps

It is essential to remember that while a class action lawsuit is initiated, a class has not yet been certified. Hence, individuals wishing to ensure their representation must act promptly. Those who prefer not to participate may remain absent class members, although they forfeit the opportunity for recoupment unless they take action. Acting quickly and securing knowledgeable legal representation can often tip the scales in favor of the investor's rights and recovery.

Final Thoughts

As the legal proceedings progress, Rosen Law Firm will keep potential class members informed through their social media channels, including LinkedIn, Twitter, and Facebook. Investors are encouraged to stay updated to ensure they maximize their opportunities for potential financial recovery. Rosen's commitment to representing shareholders epitomizes their dedication to justice in the financial landscape.

This evolving situation is a profound reminder of the importance for investors to be informed and vigilant regarding company disclosures and legal rights. The Actinium Pharmaceuticals case serves as a crucial example of investor advocacy in the wake of corporate misrepresentation.